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This work investigated the blood pressure (BP) lowering effect of the flavanol (−)-
epicatechin in a model of metabolic syndrome. Rats were fed a regular chow diet 
without (Control) or with 10% (w/v) fructose in the drinking water (high fructose, HF) 
for 8 w. A subgroup of the HF-fed rats was supplemented with (−)-epicatechin 20 
mg/kg body weight (HF-EC). Dietary (−)-epicatechin reverted the increase in BP 
caused by the fructose treatment. In aorta, superoxide anion production and the 
expression of the NADPH oxidase (NOX) subunits p47phox and p22phox were 
enhanced in the HF-fed rats. The increase was prevented by (−)-epicatechin. Similar 
profile was observed for NOX4 expression. The activity of aorta nitric oxide synthase 
(NOS) was increased in the HF group and was even higher in the HF-EC rats. These 
effects were paralleled by increased endothelial NOS phosphorylation at the 
activation site Ser1177. Among the more relevant MAPKs pathways in vascular 
tissue, JNK was shown to be activated in the aorta of the HF-fed rats and (−)-
epicatechin supplementation mitigated this activation.  
Thus, the results suggest that dietary (−)-epicatechin supplementation prevented 
hypertension in HF-fed rats decreasing superoxide anion production and elevating 
NOS activity favoring an increase in NO bioavailability. 
 
 






















Abbreviations: BP, blood pressure; BSA, bovine serum albumin; EC, (−)-
epicatechin; ERK, mitogenic extracellular signal-regulated protein kinase; HDL, high 
density lipoprotein; HF, high fructose; LDL, low density lipoprotein; JNK, c-Jun-N-
terminal kinase; L-NAME, Nω-nitro-L-arginine methyl ester; MAPK, mitogen-activated 
protein kinase; MS, metabolic syndrome; NOS, nitric oxide synthase; NOX, NADPH 
















Increased blood pressure (BP) is found with high frequency in metabolic syndrome 
(MS) patients [1] and it is associated to endothelial dysfunction [2]. Endothelial 
dysfunction, mechanistically defined as an impairment of endothelium-dependent 
vasorelaxation, is caused by a decrease in nitric oxide (NO) bioavailability in the 
vascular wall [3]. 
A decline in NO bioavailability may be caused by an ineffective NO synthesis and/or 
accelerated NO degradation. Under physiological conditions NO is mainly produced 
in the vasculature by the endothelial nitric oxide synthase (eNOS) isoform [4-5]. NO 
is degraded by superoxide anion in a near diffusion-limited rate reaction [6-8]. eNOS 
activity is regulated by substrate availability, phosphorylation, protein-protein 
interactions and subcellular localization [9]. The NOX family is a major source of 
superoxide anion in the vascular wall through the NOX1 and NOX2 isoforms [10-13]. 
Flavonoids are polyphenols present at large amounts in the human diet [14]. An 
increased intake of flavonoid-rich foods, particularly of the flavanol subfamily, has 
been associated with the prevention and/or amelioration of MS-associated risk 
factors (reviewed in [15,16]). Regarding antihypertensive effects, in 
overweight/obese subjects, a polyphenol-rich dark chocolate significantly reduced 
BP [17] and the intake of high-flavanol cocoa reduced BP in association with 
improved flow-mediated dilatation [18]. Consumption of flavanol-rich dark chocolate 
by hypertensive patients with impaired glucose tolerance, ameliorated insulin 
sensitivity and decreased BP [19]. It has been shown that the beneficial effects of 
cocoa on human vascular function may be mediated by the flavanol (−)-epicatechin 
[20]. (−)-Epicatechin is one of the most abundant flavonoids in human diets, being 
present in high concentrations in grapes, cocoa, tea, and many other fruits and 
vegetables. Mechanistic studies by using pure (−)-epicatechin were carried out in 
experimental models. Dietary (−)-epicatechin was effective in reducing BP in a rat 
model of decreased NO production-induced hypertension [21,22] and in 
spontaneously hypertensive rats [23]. The administration of (−)-epicatechin did not 
improve the increase in BP caused by the chronic inhibition of NO synthesis with L-
NAME in rats [24]. Nevertheless, the same (−)-epicatechin treatment was effective in 
reducing BP in deoxycorticosterone acetate-salt-induced hypertension rats [25].  
In this study we observed that (−)-epicatechin supplementation prevented the 
increase in BP associated with high fructose consumption. This effect can be in part 














anion production (concomitant with decreased levels of NOX subunits expression) 
and augmentation of NOS activity. In addition, (−)-epicatechin attenuated c-Jun-N-
terminal kinase (JNK) activation produced by high fructose consumption. 
 




Primary antibodies for p47phox (sc-7660), p22phox (sc-11712), eNOS (sc-654), 
caveolin-1 (sc-70516), p-JNK (Thr183/Tyr185) (sc-6254), JNK (sc-572), p-ERK 
(Tyr204) (sc-7383), ERK 1 (sc-93), p38 (sc-7149) and β-actin (sc-47778) were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies for p-eNOS 
(Ser1177) (#9570) and p-p38 (Thr180/Tyr182) (#9211) were from Cell Signalling 
Technology (Boston, MA, USA). Cy3-conjugated rabbit anti-goat was from Jackson 
ImmunoResearch Laboratories (West Grove, PA, USA). (−)-Epicatechin, β-
nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate 
(NADPH); N,N’-dimethyl-9,9’–biacridinium dinitrate (lucigenin), and bovine serum 
albumin (BSA) were from Sigma Chemical Co. (St. Louis, MO, USA). Fructose was 
obtained from Droguería Saporiti (Buenos Aires, Argentina). Commercial rat chow 
was from Gepsa-Feeds (Buenos Aires, Argentina). [14C] L-arginine was from Perkin 
Elmer Life and Analytical Sciences (Boston, MA, USA). 
 
2.2. Animals and animal care 
 
All procedures were in agreement with standards for the care of laboratory animals 
as outlined in the NIH Guide for the Care and Use of Laboratory Animals.  All 
procedures were performed according to institutional guidelines for animal 
experimentation and were approved by the Technical and Science Secretary at the 
National University of Cuyo School of Medicine. Rats were housed under conditions 
of controlled temperature (21-25ºC) and humidity with a 12 h light/dark cycle. Thirty-
days-old male Sprague-Dawley rats, weighing 100-130 g, were randomly divided into 
3 groups (10 rats per group) that were fed a standard rat chow diet and water ad 
libitum (control group, Control), the chow diet and water supplemented with 10% 
(w/v) fructose (high fructose group, HF), or the chow diet supplemented with 20 mg 
(−)-epicatechin (EC)/kg body weight [26], and the fructose-supplemented water (HF-














measured by tail plethysmography in conscious, prewarmed, slightly restrained rats 
and recorded on a Grass Model 7 polygraph (Grass Instruments Co., Quincy, MA, 
USA) at the beginning (0 w), middle (4 w), and end (8 w) of the study. After 8 w on 
treatment, and after an overnight fast, rats were weighted, anesthetized with 
ketamine (50 mg/kg body weight) and acepromazine (1 mg/kg body weight). Blood 
was collected from the abdominal aorta into heparinized tubes, and plasma was 
obtained after centrifugation at 1,000 x g for 15 min at 4ºC. Aortas were dissected 
and placed into Krebs solution (20 mM HEPES buffer, pH 7.4, containing 119 mM 
NaCl, 4.7 mM KCl, 1 mM MgSO4, 0.4 mM NaH2PO4, 0.15 mM Na2HPO4, 5 mM 
NaHCO3, 1.25 mM CaCl2, 5.5 mM glucose) and stored at -80ºC for subsequent 
biochemical procedures or processed for immunohistochemistry.  
 
2.3. Metabolic measurements 
 
Glucose, triglycerides, total and HDL-cholesterol levels were measured in plasma 
using commercially available kits (GTLab, Rosario, Argentina) following the 
manufacturer´s protocol. 
 
2.4. Aorta morphometry 
  
Part of the thoracic aorta was fixed in 10% (w/v) formaldehyde and embedded in 
paraffin. Tissues sections (5 m) were stained with hematoxylin-eosin. Micrographs 
were collected with a Cool Snap digital camera using an Olympus BX50 microscope. 
Aorta wall thickness and lumen area were calculated using Image J (National 
Institute of Health, Bethesda, Maryland, USA) according to Xiong et al [27].  
 
2.5. Determination of vascular NOS activity 
 
Vascular NOS activity was measured using [14C]L-arginine as substrate in aortic 
slices [28]. Specific NOS activity was assessed in the presence of 10-4 M L-NAME. 
NO production (measured as pmol of [14C]L-citrulline) in each tube was normalized 
to the weight of the tissue slices incubated with the substrate during equal periods of 
time and expressed as pmol/g.min. 
 















NADPH-dependent superoxide anion production in aorta homogenates was 
measured using the lucigenin-enhanced chemiluminescence assay [29]. Sample 
aliquots containing 200 g of aorta protein, were placed on vials containing warm 
(37ºC) Krebs solution, and subsequently added with NADPH (40 M final) and 
lucigenin (25 M final) in a volume of 1 ml. Each sample was measured in the 
absence and presence of superoxide dismutase (SOD) (100 U/ml). Light emission 
was measured for 10 min using a LKB Wallac 1209 Rackbeta Liquid Scintillation 
Counter (Turku, Finland) in the chemiluminescence mode, and the area under the 
curve (AUC) was calculated. Results are expressed as the difference between AUC 
in the absence and in the presence of SOD, representing the total amount of 
superoxide anion production.  
 
2.7. Western blots  
 
Aorta homogenates were added with a 2X solution of SDS-sample buffer (62.5 mM 
Tris-HCl buffer, pH 6.8, containing 2% (w/v) SDS, 25% (v/v) glycerol, 5% (v/v) -
mercaptoethanol, and 0.01% (w/v) bromophenol blue), and then heated at 95°C for 2 
min. Aliquots containing 30-50 μg of protein were separated by reducing 10% (w/v) 
polyacrylamide gel electrophoresis, and electroblotted to polyvinylidene difluoride 
membranes. Colored molecular weight standards (GE Healthcare, Piscataway, NJ, 
USA) were run in simultaneous. Membranes were blocked for 2 h in 5% (w/v) nonfat 
milk and incubated overnight in the presence of the corresponding antibodies 
(1:1,000 dilution) in 5% (w/v) BSA in PBS containing 0.1% (v/v) Tween 20. After 
incubation for 90 min at room temperature in the presence of the corresponding 
HRP-conjugated secondary antibody (1:10,000 dilution), complexes were visualized 
by chemiluminescence detection. Films were scanned and densitometric analysis 




2.8. Immunohistochemistry  
 
Aortas were post-fixed in a solution of 4 % (w/v) paraformaldehyde in PBS for 20 min 
at room temperature, followed by washing in PBS, and cryoprotection in 30 % (w/v) 














a Leica CM 1850 cryotome (Leica Microsystems Inc., Buffalo Grove, IL, USA). For 
immunohistochemistry, cryotome sections were rinsed twice with PBS, followed by a 
third rinse with PBS containing 0.3 % (v/v) Tween 20 (PBST), and then blocked for 2 
h at 37ºC with a solution containing 5% (w/v) BSA in PBST. Incubation with the 
primary antibody for p47phox (1:50) was done overnight at 4ºC in a humidified 
chamber. Sections were incubated with a Cy3-conjugated rabbit anti-goat antibody 
(1:1000) for 2 h, cell nuclei were stained with Hoechst 33342 [30]. Microscopic 
observations were done by epifluorescence using an Olympus BX50 microscope, 
and photography was carried out with a Cool Snap digital camera. Integrated optical 
density was measured as relative to area and was determined for each sample in 5 
randomly selected fields. Evaluation of the data was carried out using the Image-Pro 
Plus version 4.5 software (Media Cybernetics, Silver Spring, MD, USA).  
 
2.9. Statistical analysis 
 
Data were analyzed by one-way analysis of variance (ANOVA) using StatView 5.0 
(SAS Institute, Cary, NC, USA). Fisher's least significance difference test was used 
to examine differences between group means. A p <0.05 was considered statistically 




3.1. (−)-Epicatechin improves BP and metabolic parameters in HF-fed rats 
 
No differences in total body weight and cardiac weight index were found between the 
three experimental groups (Table 1). The ratio total cholesterol /HDL-cholesterol was 
significantly higher in the HF-group respect to Control and HF-EC groups. 
Consumption of fructose in the drinking water resulted in increased systolic BP in the 
HF group recorded after 4 and 8 w in treatment. This increase was not observed in 
the HF-EC group. The ratio between wall thickness and lumen diameter in aorta, 
determined to evaluate changes in aorta architecture, resulted similar among the 
groups indicating the absence of remodeling processes. 
 















Superoxide anion production was evaluated measuring NADPH-driven SOD-
inhibitable lucigenin chemiluminescence. Chemiluminescence was significantly 
higher in the HF group compared to the Control group (Control = 1.0 ± 0.1 AUC/mg 
prot, HF = 1.8 ± 0.1 AUC/mg prot, p<0.05) and this higher level was not observed in 
the HF-EC group (Fig. 1A). 
The expression of NOX subunits p47phox, p22phox and NOX4 (Fig. 2) was higher in 
the aortas from HF group respect to Control and HF-EC groups. The 
expression/distribution of p47phox was evaluated by immunohistochemistry across the 
aortic wall (Fig. 1 B-C). The fluorescent signal was observed in the intima and 
adventitia layers of the aorta and was markedly higher in HF rats compared to 
controls, whereas this signal was decreased by (−)-epicatechin treatment.  
 
3.3 (−)-Epicatechin increases arterial NOS activity in HF-fed rats 
 
Figure 3 shows NO related parameters in aorta from the three experimental groups. 
NOS activity was slightly but significantly higher in the HF group compared to 
controls; in the HF-EC group NOS activity was significantly higher than in both, 
Control and HF groups (Fig. 3A). To assess the possible mechanisms involved in 
aorta NO production changes, we studied eNOS protein expression and 
posttranslational modifications. Although similar eNOS protein abundance was 
observed in the three experimental groups (Fig. 3B), HF and HF-EC groups exhibited 
significantly enhanced eNOS phosphorylation ratio at the activation site Ser1177 in 
comparison with the Control group (Fig. 3C). With the purpose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
of evaluating the most relevant protein-protein interaction involved in eNOS activity 
regulation (caveolin-1/eNOS), caveolin-1 expression was measured by Western blot 
in aorta homogenates (Fig. 3D). Results showed an augmentation in caveolin-1 
expression in the HF respect to the Control group that was not observed in the HF-
EC group.  
 
3.4. (−)-Epicatechin decreases the activation of the c-Jun-N-terminal kinase pathway 
in HF-fed rats 
  
MAPK activation was evaluated in aorta homogenates through the determination of 
the ratio phosphorylated/total levels by Western blot (Fig. 4). Fructose administration 
caused an increase in c-Jun-N-terminal kinase (JNK) phosphorylation (Thr 183/Tyr 














4). (−)-Epicatechin dietary supplementation prevented the fructose-induced increase 





This work shows that the dietary administration of (−)-epicatechin prevents the 
increase in BP induced by long-term high fructose consumption in rats. (−)-
Epicatechin regulates NO bioavailability in part through the modulation of superoxide 
anion production (and NOX subunits expression), and NOS activity. 
Under the used experimental conditions, and in agreement with previous reports 
[31], BP augmentation in HF group was not associated with cardiac hypertrophy or 
aorta remodeling. According to the NO bioavailability hypothesis, the quantitative 
relationship between superoxide anion and NO is crucial in defining NO steady state 
levels, and as a consequence, its bioavailability. A higher production of superoxide 
anion is associated to hypertension [32] and compromises NO bioavailability.  
Explaining the antihypertensive effects of (−)-epicatechin through direct antioxidant 
mechanisms, such as free radical scavenging, is unlikely [33-35], due to the low 
concentration of (−)-epicatechin and its metabolites present in plasma and potentially 
reaching endothelial cells [22,36,37]. Therefore, the regulation of translational and 
posttranslational processes by (−)-epicatechin, in this case related with NOS and 
NOX expression/activity, could provide a better explanation [38-41]. 
NOX1 and NOX2 activities are regulated by the abundance of both stabilizer (e.g. 
p22phox) and activator subunits (e.g. p47phox) [42]. Under our experimental conditions, 
the increase in aortic superoxide anion production observed in the HF group was 
associated with higher expression of both p22phox and p47phox. In line with this, the 
decrease in superoxide anion production in aorta detected in the HF-EC respect to 
the HF group should be ascribed to a lower assembly/activity of NOX1 and/or NOX2 
as a consequence of the downregulation of p22phox and/or p47phox. In agreement, 
similar changes in NOX subunits expression were associated with dietary (−)-
epicatechin supplementation in other hypertension models [22,25,43]. 
Concerning NO production, the increase in aortic NOS activity in fructose treated 
rats could be ascribed to a compensatory mechanism in response to the elevation of 
BP [44]. Interestingly, this compensation was not paralleled with an increased eNOS 
expression (expected for a long-term adaptative response), but with increased eNOS 
phosporylation. Molecular mechanisms of eNOS activity regulation includes 














sites (Thr 495) [45]. In vitro studies showed that 1 M (−)-epicatechin treatment of 
human coronary artery endothelial cells in culture increased phosporylation at 
Ser1177 and Ser633 and decreased phosphorylation at Thr495 [46]. We currently 
observed a higher phospho-eNOS (Ser1177)/eNOS ratio in the aorta of the group 
receiving simultaneously fructose and (−)-epicatechin (HF-EC) respect to the Control 
group, in agreement with previous studies [24,25]. However, as in the group treated 
with fructose alone (HF group) there was also an increased in Ser1177-
phosphorylation, it is not possible to unequivocally attribute the higher NOS activity 
found in the HF-EC group to an increased phosphorylation. 
In addition, eNOS activity in endothelial cells is tightly regulated at a posttranslational 
level by a protein-protein interaction with caveolin-1 [47]. In this regard, the 
increased expression of caveolin-1 observed in the HF group would be associated 
with a negative modulation of eNOS in endothelial cells. Accordingly, similar 
caveolin-1 levels in the Control and HF-EC groups suggest a lack of negative 
modulation.  
A role for caveolin-1 in NOX assembly has also been proposed in vascular smooth 
muscle cells as well as in endothelial cells [48]. Thus, increased abundance of 
caveolin-1 is associated to lower eNOS activity and higher assembly of NOX1 and 
NOX2.  
Mechanisms of NOX4 modulation in endothelial and smooth muscle cells are 
controvertial [32]. NOX4 expression has been found increased in vessels of diabetic 
mice [49] and some authors consider that NOX4 contributes to vascular injury [50]. 
In line with this, the increased NOX4 expression observed in this work appears 
associated to not desirable effects. The proposed primarily product of NOX4 
enzymatic activity, hydrogen peroxide, participates in signal transduction regulation, 
in particular of the MAPK pathways.  
Among the more relevant MAPKs pathways in vascular tissue, JNK was shown to be 
activated in the aorta of the rats fed with high fructose diet. Accordingly, JNK 
activation by fructose consumption was previously showed in liver [26,51], skeletal 
muscle [52], and adipose tissue [26,52]. In this study, EC supplementation mitigated 
HF-mediated JNK activation in aorta, as in liver and adipose tissue of rats under the 
same experimental model [26].  
At vascular level, superoxide anion [53], hydrogen peroxide [54] and even 
peroxynitrite [55] have been considered as responsible for JNK activation. Moreover, 
NOX inhibitors antagonized the stimulatory effect of angiotensin II on JNK [53,56], 














In this regard, NOX and JNK activation upon high fructose consumption suggest a 
perturbation of cellular redox status which in the long term could lead to oxidative 
damage and irreversible changes in vascular health.  
The amount of (−)-epicatechin provided to the rats (equivalent to 200 mg/d for a 70 
kg human being) is 8-16 times higher than that estimated for the diet of most non-
vegetarian populations [57,58]. These levels of consumption could be realistically 
reached by: i) increasing fruits and vegetables consumption (most world populations 
consume less than half that the recommended 5 portions/d); ii) increasing 
specifically the consumption of (−)-epicatechin- and/or flavanol-rich fruits and 
vegetables; and/or iii) supplementing the diet or by pharmacological administration of 
pure (−)-epicatechin or flavanols. 
In summary, dietary (−)-epicatechin supplementation prevents hypertension 
developed in high fructose-fed rats concomitantly with modifications in superoxide 
anion and NO metabolism that results in an increase in NO bioavailability. 
Considering the abundance of (−)-epicatechin in some edible plants and products 
derived from them, it is feasible to develop diets enriched in those foods to avoid or 
prevent the increase in BP that occurs with age and is associated to metabolic 
syndrome. Moreover, the application of pure (−)-epicatechin as a pharmacological 
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Legends to Figures 
 
Fig. 1.  
Effect of dietary (−)-epicatechin on aorta NADPH-dependent superoxide anion 
production and p47phox subunit expression in HF-fed rats. (A) Superoxide anion 
production measured by lucigenin chemiluminescence in aortic homogenates from 
Control, HF and HF-EC groups after 8 w of treatment. Results are expressed as the 
difference between area under the curve (AUC) in the presence and the absence of 
SOD. (B-C) Quantification and representative images of p47phox 
immunohistochemistry from Control, HF and HF-EC groups. Left column shows 
p47phox protein (red). Central column shows elastin autofluorescence (green). Right 
column shows the p47phox protein (red) merged with elastin autofluorescence 
(green). In all the images blue fluorescence indicates nuclear staining with Hoechst. 
Values are shown as means ± ESM (n = 4 per group). * p < 0.05 with respect to 
Control and HF-EC groups. 
 
Fig. 2. 
Effect of dietary (-)-epicatechin on aortic expression of NOX subunits in HF-fed 
rats. Western blot of (A) p47phox, (B) p22phox, and (C) NOX4 in aortic homogenates 
from Control, HF and HF-EC groups after 8 w of treatment. -tubulin levels were 
measured as loading control. Values are shown as means ± ESM (n = 6 per group). * 
p < 0.05 with respect to Control and HF-EC groups. 
 
Fig. 3. 
Effect of dietary (-)-epicatechin on NO production related parameters in aorta 
from HF-fed rats. (A) NOS activity; Western blot of (B) eNOS, (C) p-eNOS 
(Ser1177) and (D) caveolin-1 in aortic homogenates from Control, HF and HF-EC 
groups after 8 w of treatment. Phosphorylated/total ratio was calculated for p-eNOS 
and eNOS and caveolin-1 were normalized to -tubulin content. Values are shown as 
means ± ESM (n = 5 per group). * p < 0,05 with respect to Control and HF-EC 
groups. & p < 0.05 with respect to Control and HF groups. # p < 0.05 with respect to 
Control. 
 
Fig. 4.   
Effect of dietary (-)-epicatechin on aorta MAPKs signaling pathways in HF-fed 
rats. Western blot of (A) p-ERK (Tyr204), (B) p-JNK (Thr183/Tyr185) and (C) p-p38 
(Thr180/Tyr182) in aortic homogenates from Control, HF and HF-EC groups after 8 
w of treatment. Results are expressed as the ratio of phosphorylated/total protein 
level. Values are shown as means ± ESM (n = 5 per group). * p < 0.05 with respect 
















Table 1  
Body weight, heart weight, cardiac weight index, plasma total cholesterol/HDL 
cholesterol ratio, and aorta wall thickness/lumen diameter ratio after 8 w on 
treatments and systolic blood pressure at 0, 4 and 8 w on treatments.  
 
Parameters                      Control                   HF                        HF-EC 
 
BW (g)                              336 ± 13                310 ± 13               322 ± 14 
HW (g)                             1.14 ± 0.06            1.02 ± 0.05            1.13 ± 0.05 
HW/BW                            3.4 ± 0.1                3.29 ± 0.09            3.51 ± 0.05 
Plasma TC/HDL-C           2.4 ± 0.1                3.5 ± 0.4*              1.72 ± 0.08 
WT/LD (m/mm)              65 ± 1                    59 ± 3                    66 ± 2 
SBP (mmHg) 
       0 w        109 ± 2                  112 ± 2                   112 ± 2 
           4 w        121 ± 2                  132 ± 2*                 124 ± 1 
            8 w        130 ± 4                  142 ± 3*                 130 ± 2 
BW: body weight; HW: heart weight; TC/HDL-C: ratio total cholesterol/HDL 
cholesterol; WT/LD: ratio wall thickness/lumen diameter; SBP: blood pressure; 
Values are shown as means ± ESM (n = 10 per group). 
* p < 0.05 with respect to Control and HF-EC groups.  
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